Glenmark Pharmaceuticals Limited (GLENMARK)
Investor Presentation
AI summary
- Consolidated Q4 FY26 revenue Rs 37,706 mn, +15.8% y-y; EBITDA Rs 7,626 mn, margin 20.2%; PAT Rs 3,013 mn, margin 7.6%
- India business grew 8.2% in Q4 FY26 with strong oncology and consumer care growth
- North America revenue up 29.4% in Q4, launched 13 new products, FloVent HFA generic with exclusivity
- Europe grew 21.4% in Q4, strong branded respiratory portfolio and WINLEVI launch
- Emerging Markets grew 13.7%, RYALTRIS launched in China, Thailand; Brazil launch planned FY27
- Oncology pipeline advancing with ISB 2001 Phase 1 enrolment progressing; multiple immunology assets in development
- Monroe manufacturing facility received US FDA EIR with VAI classification
- Chairman: focus on disciplined execution, differentiated science, and global impact
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GLENMARK — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GLENMARK to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Glenmark Pharmaceuticals Limited
Important.
The summary above is generated automatically from Glenmark Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.